TheStreet Quant Ratings rates Inovio Pharmaceuticals Inc (NYSEMKT:INO) Pharmaceuticals as a sell. The company’s weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share. Inovio Pharmaceuticals Inc (NYSEMKT:INO) shares after opening at $3.18 moved to $3.20 on last trade day and at the end of the day closed at $3.00. Company price to sales ratio in past twelve months was calculated as 53.25 and price to cash ratio as 13.67. Inovio Pharmaceuticals Inc (NYSEMKT:INO) showed a negative weekly performance of -9.91%.
A corporation specialized in biopharmaceutical R&D and oncology; CytRx Corporation (NASDAQ:CYTR) is investing hugely in recent findings to improve the phase of medical procedures. However, while it is slowly moving towards making new investments and carving out new niches, there are some hiccups in the form of litigation that seems to slow down the process a bit.CytRx Corporation (NASDAQ:CYTR) shares fell -7.85% in last trading session and ended the day on $3.17. CYTR return on equity ratio is recorded as -287.90% and its return on assets is -146.40%. CytRx Corporation (NASDAQ:CYTR) yearly performance is 9.31%.
Synthetic Biologics, Inc. (nysemkt:SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, reported financial results for the year ended December 31, 2013 and provided operational highlights. General and administrative expenses increased to $5.8 million for the year ended December 31, 2013, compared to $5.0 million for the same period in 2012. The increase of 16% is primarily the result of bad debt expense of $763,000 associated with the determination that the note and interest receivable from the sale of Adeona Clinical Laboratory is uncollectible. Charges related to stock-based compensation were $1.3 million for the year ended December 31, 2013, compared to $1.5 million for the same period in 2012. Synthetic Biologics Inc (NYSEMKT:SYN) shares moved up 5.98% in last trading session and was closed at $2.48, while trading in range of $2.26-$2.56. Synthetic Biologics Inc (NYSEMKT:SYN) year to date performance is 62.09%.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced the availability of HETLIOZ(TM). HETLIOZ(TM) is the first treatment approved by the U.S Food and Drug Administration (FDA) for Non-24-Hour Sleep-Wake Disorder (Non-24), a serious chronic circadian rhythm disorder that affects up to 70 percent of people who are totally blind.Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) weekly performance is -16.24%. On last trading day company shares ended up $14.03. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) distance from 50-day simple moving average is -6.25%. Analysts mean target price for the company is $24.33.